Treatment options for alopecia: an update, looking to the future

被引:27
作者
Miteva, Mariya [1 ]
Tosti, Antonella [1 ]
机构
[1] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, RSMB, Miami, FL 33136 USA
关键词
alopecia areata; androgenetic alopecia; cicatricial alopecia; clobetasol; corticosteroids; discoid lupus erythematosus; dutasteride; finasteride; folliculitis decalvans; hair loss; hydroxychloroquine; isotretinoin; lichen planopilaris; minoxidil; pioglitazone; PRP; scalp; topical immunotherapy; treatment; FRONTAL FIBROSING ALOPECIA; CUTANEOUS LUPUS-ERYTHEMATOSUS; PRIMARY CICATRICIAL ALOPECIAS; 308-NM EXCIMER-LASER; PATTERN HAIR LOSS; FINASTERIDE; MG; TERM-FOLLOW-UP; ANDROGENETIC ALOPECIA; LICHEN-PLANOPILARIS; DOUBLE-BLIND;
D O I
10.1517/14656566.2012.685160
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Hair loss is a very common complaint. The diagnosis is based on clinical, dermoscopic and pathological examination. The treatment is usually continuous and requires strong compliance. Areas covered: This article aims to i) summarize current treatment options for the most common forms of hair loss; ii) update the literature on treatment options to emerge over the 3 years since the release of the first edition of this article in 2009 [1] Tosti A, Duque-Estrada B. Treatment strategies for alopecia. Expert Opin Pharmacother 2009; 10(6): 1017-1026.; and iii) outline future strategies for treating alopecia. Expert opinion: There is good evidence-based information for the treatment of androgenetic alopecia. There are very few good-quality randomized studies, and no information about long-term results for most of the available treatments for alopecia areata and cicatricial alopecias. Significant research success has been achieved over the past few years through i) discovering the genetic profile of alopecia areata; ii) working on follicular neogenesis in androgenetic alopecia; and iii) discovering the PPAR-g pathway in scarring alopecia.
引用
收藏
页码:1271 / 1281
页数:11
相关论文
共 98 条
[91]   Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA [J].
Wenzel, J ;
Uerlich, M ;
Wörrenkämper, E ;
Freutel, S ;
Bieber, T ;
Tüting, T .
BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (05) :1011-1015
[92]   Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus [J].
Wenzel, Joerg ;
Zahn, Sabine ;
Bieber, Thomas ;
Tueting, Thomas .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2009, 301 (01) :83-86
[93]   Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women [J].
Whiting, DA ;
Waldstreicher, J ;
Sanchez, M ;
Kaufman, KD .
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 1999, 4 (03) :282-284
[94]  
Wiseman M C, 1999, J Cutan Med Surg, V3 Suppl 3, pS45
[95]  
Wiseman MC, 2001, ARCH DERMATOL, V137, P1063
[96]   Thalidomide: dermatological indications, mechanisms of action and side-effects [J].
Wu, JJ ;
Huang, DB ;
Pang, KR ;
Hsu, S ;
Tyring, SK .
BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (02) :254-273
[97]   Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouse [J].
Zheng, Y ;
Eilertsen, KJ ;
Ge, L ;
Zhang, L ;
Sundberg, JP ;
Prouty, SM ;
Stenn, KS ;
Parimoo, S .
NATURE GENETICS, 1999, 23 (03) :268-270
[98]  
Zimber MP, 2011, J DRUGS DERMATOL, V10, P1308